Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | DeFi trial: nirogacestat vs placebo for patients with progressing desmoid tumors

Robin Jones • 1 Nov 2022
ESMO 2022
Sarcoma Nirogacestat
DeFi

Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the randomised Phase III DeFi trial (NCT03785964) investigating nirogacestat compared to placebo for patients with progressing desmoid tumors. The primary endpoint of the trial was progression free survival (PFS). The trial was positive and the safety profile was good, however Prof. Jones highlights the risks of ovarian suppression. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robin Jones

0:58
Challenges in advanced GIST: tackling resistance to therapies
Robin Jones • 4 Jun 2023
0:36
Current treatment landscape for patients with advanced gastrointestinal stromal tumor (GIST)
Robin Jones • 3 Jun 2023
1:13
Updated overall survival findings from the Phase III INTRIGUE trial
Robin Jones • 4 Jun 2023
0:34
INTRIGUE: ripretinib versus sunitinib in GIST
Robin Jones • 4 Jun 2023

Related Videos

1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
1:29
Developments for TILs and TCR modified cell therapy in solid tumors
Sebastian Klobuch • 7 Apr 2024
0:46
Highlights in sarcoma at ESMO 2023
Robin L. Jones • 22 Oct 2023
0:49
Advancing sarcoma treatment: insights on combinations and trials
Robin L. Jones • 22 Oct 2023
The content of VJOncology is intended for healthcare professionals